遠大醫藥(00512.HK):集團引進的創新放射性核素偶聯產品ITM-11在中國加入的國際多中心III期臨牀試驗完成了首例患者入組給藥
格隆匯3月19日丨遠大醫藥(00512.HK)公吿,集團引進的創新放射性核素偶聯("RDC")產品 ITM-11 在中國加入的國際多中心 III 期臨牀試驗("COMPOSE 試驗"),近日完成了首例患者入組給藥。此前,集團於2021年12月與 ITM Isotope Technologies Munich SE("ITM SE")簽署了產品戰略合作協定,並獲得其開發的包括 ITM-11 及 ITM-14D(TOCscan®)在內的三款創新 RDC 產品在大中華區(中國大陸、中國香港特別行政區、中國澳門特別行政區、中國台灣地區)的獨家開發、生產及商業化權益。此次COMPOSE 試驗完成在中國的首例患者入組給藥是集團在核藥抗腫瘤診療領域的又一次重大的研發進展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.